What is CRISPR Therapeutics's market cap?

CRISPR Therapeutics (CRSP) has a market capitalization of $5.8B and trades on NASDAQ.

What is CRISPR Therapeutics's revenue and profitability?

CRISPR Therapeutics generated $4.1M in trailing twelve-month revenue with a net loss of $568.5M, representing a net margin of -13856.5%, with free cash flow of -$401.2M. These figures are based on the Q1 2026 filing.

Who are CRISPR Therapeutics's competitors?

CRISPR Therapeutics's key competitors include Intellia Therapeutics, Editas Medicine, Prime Medicine, and others. These companies compete in similar markets and product categories.

Who does CRISPR Therapeutics partner with?

CRISPR Therapeutics's notable partners include Vertex Pharmaceuticals Incorporated, Sirius Therapeutics, Eli Lilly, and others.

What subsidiaries does CRISPR Therapeutics have?

CRISPR Therapeutics's subsidiaries include TRACR Hematology Ltd..

Where is CRISPR Therapeutics headquartered?

CRISPR Therapeutics is headquartered in Switzerland and employs approximately 407 people. It has been publicly traded since 2016.

CRISPR Therapeutics

CRSP

CRISPR Therapeutics is a leading biopharmaceutical company dedicated to developing transformative gene-based medicines using the CRISPR/Cas9 gene-editing platform.

Market cap

$5.83B+29.4%

Revenue$4.1M-89.1%

Net income-$568.5M-47.4%

Free cash flow-$401.2M-30.3%

EPS (diluted)-$6.20-37.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$1.5MMiss by $4.6M EPS-$1.28Miss by $0.08

Read the full report

Next report

Aug 3, 2026 (In 3 weeks)

Revenue estimate$7.4M

EPS estimate-$1.20

Financials

Q1 2026

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation & ratios

Valuation

See full

Market cap$5.83B+29.4%

Enterprise value$6.19B+36.8%

P/S1,421×+1,303×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Segments

By product

See full

Collaboration Revenue$1.0M—

Grant$458.0K-47.1%

Competitors

By market cap

CRISPR Therapeutics$5.8B+29.4%

Beam Therapeutics$3.8B+88.6%

Intellia Therapeutics$2.4B+112%

Prime Medicine$834.5M—

Regenxbio$787.4M+78.8%

Editas Medicine$563.2M+162%

Precision BioSciences, Inc.$239.4M+398%

Metagenomi Therapeutics, Inc. $48.6M-22.2%

By revenue growth

Beam Therapeutics+158%

Intellia Therapeutics+45.0%

Regenxbio-44.0%

CRISPR Therapeutics-89.1%

By net margin

Regenxbio-330.23%-230pp

Intellia Therapeutics-597.04%+557pp

Beam Therapeutics-742.72%+338pp

Prime Medicine-4,342.44%—

CRISPR Therapeutics-13,856.54%-12,833pp

Profile

CRISPR Therapeutics is a leading biopharmaceutical company dedicated to developing transformative gene-based medicines using the CRISPR/Cas9 gene-editing platform. The company focuses on precisely altering genomic DNA to treat serious human diseases across hemoglobinopathies, oncology, autoimmune disorders, and regenerative medicine. Its value proposition is centered on creating potentially curative, one-time therapies for both rare and common diseases.

Competitive position

A pioneer in the gene-editing field, being the first company to achieve global regulatory approval for a CRISPR-based therapy.

GeographiesUnited States, European Union, Great Britain, Canada, Switzerland, Middle East

Customer segmentsPatients with genetic disorders, Healthcare providers, Pharmaceutical partners

Business modelResearch and Development, Licensing and Royalties, Collaborative Development

SuppliersHealthy donor T-cell providers, Contract manufacturing organizations, Specialized laboratory equipment suppliers, Intellectual property licensors

CustomersSpecialized hospitals, Authorized treatment centers, Pharmaceutical distributors, Government and private health insurers

CountrySwitzerland

Listed2016

Employees407.0

CEOSamarth Kulkarni

SectorHealthcare

IndustryBiotechnology

Websitecrisprtx.com

FilingsSEC EDGAR

Ask your AI about CRISPR Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's market cap?: CRISPR Therapeutics (CRSP) has a market capitalization of $5.8B and trades on NASDAQ.
What is CRISPR Therapeutics's revenue and profitability?: CRISPR Therapeutics generated $4.1M in trailing twelve-month revenue with a net loss of $568.5M, representing a net margin of -13856.5%, with free cash flow of -$401.2M. These figures are based on the Q1 2026 filing.
Who are CRISPR Therapeutics's competitors?: CRISPR Therapeutics's key competitors include Intellia Therapeutics, Editas Medicine, Prime Medicine, and others. These companies compete in similar markets and product categories.
Who does CRISPR Therapeutics partner with?: CRISPR Therapeutics's notable partners include Vertex Pharmaceuticals Incorporated, Sirius Therapeutics, Eli Lilly, and others.
What subsidiaries does CRISPR Therapeutics have?: CRISPR Therapeutics's subsidiaries include TRACR Hematology Ltd..
Where is CRISPR Therapeutics headquartered?: CRISPR Therapeutics is headquartered in Switzerland and employs approximately 407 people. It has been publicly traded since 2016.